Supplementary Table 1. Sensitivity Analysis with Warfarin Bridging Patients Only Included in the Warfarin Cohort: Hospital Length of Stays (LOS) and Associated Costs per Patient for Readmissions

Readmission Type	Unadjusted		Regression Adjusted	
	Warfarin Mean (SD)	Apixaban Mean (SD)	Estimated Difference (Warfarin – Apixaban)* Mean (95% CI)	p-value
All-cause Readmission				
LOS (days)	0.34 (1.85)	0.20 (1.42)	0.12 (0.05-0.20)	0.001
Cost	$725 ($4,143)	$487 ($4,063)	$162 ($30-$321)	0.03
MB-related Readmission				
LOS (days)	0.036 (0.59)	0.009 (0.22)	0.03 (0.002-0.05)	0.03
Cost	$83 ($1,360)	$21 ($522)	$56 ($11-$145)	0.01
Any Bleeding-related Readmission				
LOS (days)	0.13 (1.48)	0.05 (0.67)	0.08 (0.02-0.14)	0.005
Cost	$308 ($3,539)	$133 ($2,213)	$73 ($25-$156)	<0.001
VTE-related Readmission				
LOS (days)	0.07 (0.69)	0.05 (0.62)	0.02 (-0.01-0.05)	0.15
Cost	$174 ($1,775)	$131 ($1,396)	$22 (-$49-$116)	0.54

The data shown are the mean (SD) across all patients in the study cohorts, including those without readmissions where the corresponding readmission LOS and cost are 0.

*Positive values indicate longer LOS and higher cost for warfarin vs. apixaban treated patients.

SD: standard deviation; MB: major bleeding; VTE: venous thromboembolism